Document:

exv10w5

Exhibit
10.5

SETTLEMENT AND LICENSE AGREEMENT

     This Settlement and License Agreement (“Agreement”) is entered into as of June 19, 2009, by
and between Plaintiff, Anthurium Solutions, Inc. (hereinafter referred to as “Anthurium” and more
fully defined below) and MedQuist Inc. (hereinafter referred to as “MedQuist” and more fully
defined below), by and through their duly authorized representatives.

RECITALS

     WHEREAS, on November 6, 2007, Anthurium initiated a lawsuit in the United States District
Court for the Eastern District of Texas, currently styled Anthurium Solutions, Inc. v. MedQuist,
Inc., et al., Civil Action No. 2:07-cv-484 (“the Lawsuit”) seeking damages for the alleged
infringement of United States Patent No. 7,031,998, entitled “Systems and Methods for Automatically
Managing Workflow Based on Optimization of Job Step Scheduling” (hereinafter referred to as “the
‘998 Patent”);

     WHEREAS, MedQuist denies the allegations set forth in the Complaint filed by Anthurium in the
Lawsuit, and has asserted affirmative defenses alleging that the ‘998 patent is invalid, not
infringed and unenforceable;

     WHEREAS, each party disputes various contentions and claims asserted by the other party in the
Lawsuit, and the parties have determined that continued litigation will be time consuming,
protracted, and expensive; and

     WHEREAS, in view of the foregoing, Anthurium and MedQuist now desire to settle the Lawsuit,
including all current causes of action between Anthurium and MedQuist, without admitting in any way
the other party’s claims or arguments, and to grant the release of one another from any and all
liability and/or obligations, past or present arising under, out of, or in any manner connected
with the alleged infringement of the ‘998 Patent and any other Anthurium Patents (defined below),
including, but not limited to, U.S. Patent No. 6,604,124 (the
“’124 Patent”), and U.S. Patent
Application No. 0195429 A1, and any potential defenses or counterclaims thereto.

     NOW, THEREFORE, Anthurium and MedQuist, after carefully reviewing this Agreement and in
exchange for the dismissal and releases of all claims and counterclaims that have been or could
have been raised by or against each other in the Lawsuit, for the monetary consideration provided
herein, and for other good and valuable considerations, the receipt and sufficiency of which is
hereby expressly acknowledged, agree as follows:

1. DEFINITIONS

     1.1. “Anthurium” means, collectively, (i) Anthurium Solutions, Inc., a Delaware corporation,
with its principal office located at 470 Atlantic Ave., Fourth Floor, Boston, Massachusetts, (ii)
the Anthurium Affiliates and Related Parties, and (iii) the respective assignees and
successors-in-interest of each of the foregoing.

     1.2. “Anthurium Affiliates and Related Parties” means (i) any Person that, at any time,
directly or indirectly, controls, is controlled by or under common control with Anthurium
(including without limitation its assign or successors-in-interest); (ii) A:/SCRIBES, LLC, a

1

 

Pennsylvania corporation with principal office at 1012 Robin Drive, West Chester, Pennsylvania, and
any Person that, at any time, directly or indirectly, controls, is controlled by or under common
control with A:/SCRIBES, LLC. (including without limitation its assigns or successors-in-interest);
(iii) Janice Archbold, including her heirs and assigns; and (iv) Timothy Simard, including his
heirs and assigns.

     1.3. “Anthurium Patents” means: (i) the ‘998 Patent and United States Patent No. 6,604,124;
(ii) any patent owned or controlled by Anthurium as of the Effective Date; (iii) any patent which
issues after the Effective Date from an application owned or controlled by Anthurium prior to the
Effective Date; and (iv) any and all patents and applications from which any or all of the patents
described in subparagraphs (i)-(iii) claim priority or are derived through continued prosecution,
division, continuation, continuation-in-part, reissue, reexamination, extension, or foreign
prosecution. 

     1.4. “Effective Date” shall mean the last date upon which this Agreement has been executed by
both Anthurium and MedQuist.

     1.5. “MedQuist” means, collectively, (i) MedQuist Inc., a New Jersey corporation, with its
corporate headquarters located at Mount Laurel, New Jersey, (ii) the MedQuist Affiliates, and (iii)
the respective assignees and successors-in-interest of each of the foregoing.

     1.6. “MedQuist Affiliate” means any Person, including but not limited to any MedQuist Company,
that, at any time, directly or indirectly, controls, is controlled by, or is under common control
with, MedQuist (including without limitation its assigns or successors-in-interest). For the
purpose of this definition and the definition of Anthurium Affiliates and Related Parties, the term
“control” means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such entity, whether through ownership of voting
securities (as to which ownership of 50% or more establishes control) or other interests, by
contract or otherwise, including, in the case of a trust, the power to appoint or remove trustees
or otherwise direct the trust’s affairs. The terms “is controlled by or “is under common control”
have the correlative meanings. For the purposes of clarity and without limitation this definition
is expressly intended to cover (a) CBay Systems Holdings, Ltd. (“CBay Holdings”) and the medical
transcription companies controlled by CBay Holdings, but (b) is expressly not intended to cover
S.A.C. PEI CB Investment, L.P. (“S.A.C.”), or any other companies controlled by S.A.C. (except in
their capacity as direct or indirect owner of MedQuist), other than the companies falling under
item (a).

     1.7. “MedQuist Company” means MedQuist Inc., MedQuist CM LLC, MedQuist IP LLC, MedQuist Canada
Company, MedQuist of Delaware, Inc., MedQuist Transcriptions, Ltd., LCH Australia, Inc., LCH Canada
or Speech Machines Limited.

     1.8. “MedQuist Product” means any product, component, device, software, system or service
made, used, sold, offered for sale, exported or imported for sale by MedQuist.

     1.9. “Owned or Controlled” means, with respect to a Anthurium’s relationship to a patent,
patent application or invention, as of the specified time being (a) owned by Anthurium, (b) owned
by a third party that is contractually obligated to assign such patent, patent application or
invention to Anthurium and (c) held under license by Anthurium, with the

2

 

sufficient rights to grant
to MedQuist the rights granted under this Agreement, including without limitation the rights
granted under Articles 2 and 3.

     1.10. “Parties” or “Party” means the signatories to this Agreement (Anthurium and MedQuist),
collectively and individually.

     1.11. “Patents” means (i) all classes or types of patents, including utility patents, utility
models, design patents, invention certificates, reexaminations, reissues, extensions and renewals,
in all jurisdictions of the world; and (ii) all applications (including provisional and
nonprovisional applications), continuations, divisionals, and continuations-in-part, for these
classes or types of patents in all jurisdictions of the world. The term “Patents” does not include
any copyrights, trademarks, mask work rights, or trade secret rights.

     1.12. “Person” means a person or legal entity, including without limitation an entity
organized as a corporation, partnership, limited liability partnership and limited liability
company.

2. RELEASES AND GRANTS

     2.1. Release of MedQuist. In consideration of the releases and rights granted in favor of and
to Anthurium in this Agreement, Anthurium hereby releases and discharges MedQuist from any and all
past or present claims, demands, actions, causes of action, suits of any kind or nature, rights,
damages, costs, losses, expenses and compensation, in each case whether known or unknown, arising
from or related to in whole or part any act occurring or circumstance arising on or before the
Effective Date, including, without limitation, any infringement of any Patent. For the avoidance of
doubt, the foregoing release shall become effective and irrevocable upon the execution of this
Agreement and the payment of the amount specified in Section 4.1.

     2.2. Release of Anthurium. In consideration of the releases and rights granted in favor of
and to MedQuist in this Agreement, MedQuist hereby releases and discharges Anthurium from any and
all past or present claims, demands, actions, causes of action, suits of any kind or nature,
rights, damages, costs, losses, expenses and compensation, in each case whether known or unknown,
arising from or related to in whole or part any act occurring or circumstance arising on or before
the Effective Date, including, without limitation, any claims that were or may
have been brought in the Lawsuit, and expressly including all claims that were the subject of
MedQuist’s motion to amend its answer and counterclaim. For the avoidance of doubt, the foregoing
release shall become effective and irrevocable upon the execution of this Agreement and the payment
of the amount specified in Section 4.1.

     2.3. Anthurium License to MedQuist. Subject to the payment provided under Section 4.1,
Anthurium hereby grants to MedQuist, and MedQuist hereby accepts, a non-exclusive, non-transferable
(subject to Section 8.1), fully paid-up, royalty-free, worldwide license, without the right to
sublicense, under the Anthurium Patents to make, have made, use, have used, import, have imported,
export, have exported, offer to sell, sell and have sold, MedQuist Products. This license shall
continue until the expiration of the last to expire of the Anthurium Patents. For the avoidance of
doubt, the license includes “have made” rights which apply to any MedQuist Product covered by an
Anthurium Patent that is manufactured or produced by a third party and sold by MedQuist.

3

 

3. LIMITED COVENANTS NOT TO ASSERT

     3.1. Covenant Not To Assert Against MedQuist. Once the payment specified in Section 4.1 is
made, for a period of three (3) years following the Effective Date, Anthurium hereby covenants not
to assert against MedQuist any claim, whether known or unknown as of the Effective Date, whether
existing in the past, currently existing or which arises after the Effective Date, which claim
arises from or is related to any infringement, misappropriation or violation of any intellectual
property right (other than a trademark right), and hereby fully and finally waives any damages that
may arise or accrue with respect to such claims during such three-year period. This covenant not
to assert shall not restrict Anthurium from bringing a counterclaim in response to any suit brought
by MedQuist against Anthurium.

     3.2. Responsibilities of the Assignees of the Patent in Suit. In the event that Anthurium
transfers or assigns ownership and/or control of any of the Anthurium Patents, such transfer or
assignment shall be subject to the release, license and covenant not to assert set forth in
Articles 2 and 3 of this Agreement, and such transfer or assignment shall not become effective
unless and until the transferee party agrees in writing to be bound by this Agreement and to accept
Anthurium’s rights and obligations hereunder as applicable to such transferred Anthurium Patents.

4. PAYMENT

     4.1. Payment and Date. In return for the licenses, release and other consideration set forth
herein, MedQuist will pay to Anthurium a lump sum of $5,750,000 U.S. Dollars and CBay Holdings will
pay to Anthurium a lump sum of $100,000 U.S. Dollars. These payments will be made within five (5)
days from the Effective Date of this agreement. Both Parties agree that this is just and fair
consideration. These payments to Anthurium shall be made to the Client Trust account of the firm
of Holland & Knight, as follows:

Bank of America IOLTA account

Bank of America

ABA #: 026009593

Account #: 9429149562

Account Name: Holland & Knight LLP IOLTA account

For further credit to: 111739.00004

5. DISMISSAL

     5.1. Dismissal. Within five (5) days of the payment described in Section 4.1, above, the
Parties shall file a Stipulation of Dismissal of the Lawsuit With Prejudice in the form attached as
Exhibit A.

     5.2. No Admission of Liability. The Parties expressly agree and acknowledge that by entering
into this Agreement no Party admits any liability, wrongdoing or the truth of any allegation
contained in any claim, defense or counterclaim alleged in the Lawsuit. Neither this Agreement nor
any release contained within it may be construed or used as an admission of any issues, facts,
wrongdoing, liability, or violation of law whatsoever.

4

 

     5.3. Each Party to Pay Its Own Legal Fees. The Parties shall each pay their own legal fees
and costs incurred in connection with the Lawsuit.

6. REPRESENTATIONS AND WARRANTIES

     6.1. Anthurium’s Sole Right and Authority. Anthurium represents and warrants that it is the
sole owner of the ‘998 Patent and the Anthurium Patents and possesses all rights necessary to grant
the releases, licenses and covenants not to assert granted to MedQuist hereunder. Anthurium
further warrants that (i) no ownership interest in the ‘998 Patent or any Anthurium Patent is held
by any third party, and (ii) the ‘998 Patent and the Anthurium Patents are not subject to any
encumbrance, lien or claim of ownership by any third party.

     6.2. Sole Owner of Claims. Each Party represents and warrants to the other Party that: (i)
it is the sole owner of the claims or causes of action released in this Agreement and has not
previously assigned or transferred, or purported to assign or transfer, any interest in such claims
or causes of action to any other person or entity; and (ii) it is not in a disparate bargaining
position with respect to the negotiation of this Agreement.

     6.3. MedQuist’s Sole Right and Authority. MedQuist represents and warrants that it has the
full authority to enter into this Agreement on behalf of MedQuist (including on behalf of all
MedQuist Affiliates and Companies) and is competent to do so; and that this Agreement constitutes
the legal, valid and binding obligation of MedQuist enforceable against MedQuist in accordance with
its terms.

     6.4. Anthurium’s Sole Right and Authority. Anthurium represents and warrants that it has the
full authority to enter into this Agreement on behalf of Anthurium (including on behalf of all
Anthurium Affiliates and Related Parties) and is competent to do so; and this Agreement constitutes
the legal, valid and binding obligation of Anthurium enforceable against Anthurium in accordance
with its terms.

     6.5. Signature Authority. The persons signing this Agreement each represent that they are
duly authorized, with full authority to bind the Parties, and that no signature of any other person
or entity is necessary to bind the Parties.

7. CONFIDENTIALITY

     7.1. Confidentiality. Except for disclosure (i) pursuant to an order or subpoena of a court
or governmental agency; (ii) to persons with a “need to know” respecting corporate, financial,
legal and contract matters, including insurers, lenders, investment bankers, auditors and
contracting partners, who also agree to treat such information as confidential; or (iii) as may
otherwise be required by law, the parties agree to keep the contents of this Agreement
confidential. In the event that production of this Agreement is responsive to a discovery request
received by a party in connection with litigation, this Agreement may be produced only if there is
a Protective Order that limits disclosure of the Agreement to outside counsel only and the
Agreement is properly designated under the provisions of the applicable Protective Order. To the
extent that a Party to this Agreement is required to disclose the financial terms of this Agreement
pursuant to applicable law, regulation, discovery request or court order, such Party shall promptly
inform the other Party of such requirement for disclosure and shall afford the

5

 

other Party
sufficient opportunity to limit such disclosure or to seek appropriate protective orders before any
information is disclosed.

     7.2. Public Statements Regarding this Agreement. Upon execution of this Agreement, Anthurium
may disclose solely that it has settled the Lawsuit with MedQuist and has granted MedQuist a
non-exclusive license, and shall not disclose any other terms of this Agreement.

8. OTHER REPRESENTATIONS, ACKNOWLEDGEMENTS AND AGREEMENTS

     8.1. Successors, Assigns and Beneficiaries. This Agreement shall inure to the benefit of and
shall be binding upon the Parties hereto and their successors, assigns, representatives, and
beneficiaries. MedQuist may assign this Agreement (i) to any MedQuist Affiliate, (ii) in
connection with the sale of the stock of MedQuist, any merger of MedQuist or the sale of
substantially all of the assets of MedQuist which relate to the subject matter of this Agreement,
to the Person that is the party to that transaction with MedQuist. In the event that, after the
Effective Date, a Person that is not at such time a MedQuist Affiliate (a) acquires control of
MedQuist through the acquisition of 50% or more of MedQuist’s securities or (b) acquires
substantially all of the assets of MedQuist, or (c)
MedQuist is merged into such Person, and at the time of such acquisition or merger, such
Person has or had in the past products or services covered by the Anthurium Patents, (the “Acquirer
Products or Services”), then following such acquisition or merger MedQuist (or in the case of an
asset acquisition or where MedQuist is merged into another entity that is not a holding company,
those portions of such acquirer or merged entity that comprise the business of MedQuist that was
acquired or merged, hereafter the “MedQuist Business”) shall continue to have all rights and
benefits hereunder for its existing and future products and services, but such rights and benefits
shall not apply to the Acquirer Products or Services or any future products or services that may be
introduced by those portions of such acquirer’s business that are distinct from MedQuist or the
MedQuist Business, as the case may be (collectively, the “Other Products”). Such Other Products
shall not be MedQuist Products hereunder and shall not have the benefit of the release, license or
covenant not to assert granted hereunder.

     8.2. Non-Cooperation. MedQuist acknowledges and agrees that the Anthurium Patents are valid.
MedQuist warrants and agrees that it shall not, directly or indirectly, challenge the validity of,
or attempt to limit the scope of, the Anthurium Patents, whether in a court proceeding, in a
reexamination proceeding, or otherwise, nor will MedQuist assist, directly or indirectly, any third
party in doing so, except (a) as required by law, regulation or court order and (b) without
limiting Sections 2.3 and 3.1, in defense to any claim asserted against MedQuist under any such
Anthurium Patent.

     8.3. Attorneys’ Fees. In any litigation, arbitration or court proceeding between the Parties
regarding the enforcement of any terms of this Agreement, the prevailing party shall be entitled to
reasonable attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this
Agreement.

     8.4. Jurisdiction and Choice of Law. This Agreement shall be interpreted, and the rights and
duties of the parties hereto shall be determined, in accordance with the laws of the State of
Delaware, without regard to its conflicts of laws provisions. Any action brought to

6

 

enforce the
provisions of this Agreement shall be commenced in the United States District Court for the Eastern
District of Texas.

     8.5. Entire Understanding. This Agreement and any attachments hereto constitute a single,
integrated written contract expressing the entire agreement of the Parties and shall not be
modified, supplemented, or repealed except by a writing signed by each of the Parties. No
covenants, agreements, representations, or warranties of any kind whatsoever have been made by any
Party, except as specifically set forth in this Agreement. All prior discussions, written
communications, and negotiations have been merged and integrated into and are superseded by this
Agreement.

     8.6. Execution of Counterparts. This Agreement may be executed in one or more counterparts,
each of which shall be deemed to be an original and all executed counterparts together shall be
deemed to be one and the same instrument.

     8.7. Construed as Jointly Prepared. This Agreement shall be construed as if the Parties
jointly prepared it and any uncertainty or ambiguity shall not be interpreted against any one Party
because of the manner in which this Agreement was drafted or prepared.

     8.8. Invalidity. If any provision of this Agreement is held invalid, illegal, or
unenforceable, the remaining provisions shall not be affected. The Parties shall consult and use
their reasonable and best efforts to agree upon a valid and enforceable provision, which shall be a
reasonable substitute for the invalid, illegal or unenforceable provision.

     8.9. Notices. All notices under this Agreement shall be in writing and delivered by facsimile
transmission, overnight express mail, same or next day courier service, or by personal delivery to
such Party at the address given below, or such other address as provided by a Party by written
notice:

	 	 	 
	     Anthurium:
	 	Anthurium Solutions, Inc.

4th Floor

470 Atlantic Ave.

Boston, MA 02210

	 	 	 

	 	 	Holland & Knight

10 St. James Ave.

Boston, MA 02116

ATTN: Jeffrey Seul

	 	 	 

	     MedQuist:
	 	MedQuist Inc.

1000 Bishops Gate Blvd., Suite 300

Mt. Laurel, NJ 08054

     8.10. Headings. The headings and captions used herein shall not be used to interpret or
construe this Agreement.

7

 

     IN WITNESS HEREOF, the Parties being fully authorized and empowered to bind themselves to this
Agreement, have authorized and executed this Agreement on the date set forth opposite their
respective signatures.

	 	 	 	 	 
	 	

ANTHURIUM SOLUTIONS, INC.

 	 
	  DATED: June 19, 2009 	By:  	/s/ TIMOTHY SIMARD
 	 
	 	 	TIMOTHY SIMARD, 	 
	 	 	Chairman and CEO 	 
	 
	 	MEDQUIST INC.

 	 
	  DATED: June 19, 2009 	By:  	/s/ MARK R. SULLIVAN
 	 
	 	 	MARK R. SULLIVAN 	 
	 	 	General Counsel 	 
	 
	 	A:/SCRIBES, LLC

 	 
	  DATED: June 19, 2009 	By:  	/s/  JANICE ARCHBOLD
 	 
	 	 	JANICE ARCHBOLD 	 
	 	 	 	 
	 
	 	Janice Archbold, and her heirs and assigns

 	 
	  DATED: June 19, 2009 	By:  	/s/ JANICE ARCHBOLD
 	 
	 	 	JANICE ARCHBOLD 	 
	 	 	 	 
	 
	 	Timothy Simard, and his heirs and assigns

 	 
	  DATED: June 19, 2009 	By:  	/s/ TIMOTHY SIMARD
 	 
	 	 	TIMOTHY SIMARD 	 
	 	 	 	 

8

 

	 	 	 	 	 

EXHIBIT A

IN THE UNITED STATES DISTRICT COURT

FOR THE EASTERN DISTRICT OF TEXAS

MARSHALL DIVISION

	 	 	 	 	 
	ANTHURIUM SOLUTIONS, INC.,

	 	§	 	 
	 

	 	§	 	 
	 

	 	§
	 	Civil Action No. 2:07-cv-484 (DF/CE)
	 

	 	§	 	 
	 

	 	§	 	 
	Plaintiff,

	 	§
	 	JURY
	 

	 	§	 	 
	v.

	 	§	 	 
	 

	 	§	 	 
	MEDQUIST INC., ARRENDALE

	 	§	 	 
	 

	 	§	 	 
	ASSOCIATES, INC. and SPHERIS, INC.,

	 	§	 	 
	 
	Defendants.
	 	 	 	 

STIPULATION OF DISMISSAL WITH PREJUDICE

     IT IS STIPULATED, by and among Plaintiff Anthurium Solutions, Inc. (“Anthurium”) and MedQuist
Inc.. (“MedQuist”) (together, the “Parties”), through their counsel of record and subject to the
approval of the Court that:

     (1) All claims presented by Anthurium’s Complaint as to MedQuist, as well as all of MedQuist’s
counterclaims, shall be dismissed with prejudice as to each of these parties;

     (2) This Stipulation of Dismissal With Prejudice shall not serve to operate as a dismissal of
any other party named as a defendant in this action; and

9

 

     (3) The Parties shall bear their own costs and attorneys’ fees.

	 	 	 
	/s/ Joshua Krumholz

	 	/s/ Bryan Farney
	 

	 	 
	ATTORNEYS FOR PLAINTIFF

ANTHURIUM SOLUTIONS, INC.

	 	ATTORNEYS FOR DEFENDANT

MEDQUIST INC.

CERTIFICATE OF SERVICE

     I hereby certify that the following counsel of record who are deemed to have consented to
electronic service are being served this ___day of June, 2009, with a copy of this document via
the Court’s CM/ECF system per Local Rule CV-5(a)(3). Any other counsel of record will be served by
electronic mail, facsimile transmission and/or first class mail on this same date.

/s/
Joshua
Krumholz                     

10

 

IN THE UNITED STATES DISTRICT COURT

FOR THE EASTERN DISTRICT OF TEXAS

MARSHALL DIVISION

	 	 	 	 	 
	ANTHURIUM SOLUTIONS, INC.,

	 	§	 	 
	 

	 	§	 	 
	 

	 	§
	 	Civil Action No. 2:07-cv-484 (DF/CE)
	 

	 	§	 	 
	 

	 	§	 	 
	Plaintiff,

	 	§
	 	JURY
	 

	 	§	 	 
	v.

	 	§	 	 
	 

	 	§	 	 
	MEDQUIST INC., ARRENDALE

	 	§	 	 
	 

	 	§	 	 
	ASSOCIATES, INC. and SPHERIS, INC.,

	 	§	 	 
	 
	Defendants.
	 	 	 	 

ORDER

     Before the Court is Plaintiff Anthurium Solutions, Inc.’s (“Anthurium”) and MedQuist Inc.’s
(“MedQuist”) Stipulation of Dismissal With Prejudice, which is hereby GRANTED.

     Accordingly, the claims presented by Anthurium’s Complaint as to MedQuist are hereby dismissed
with prejudice as to each of these parties only.

     IT IS FURTHER ORDERED that each party shall bear its own costs.

11exv10w1

Exhibit 10.1

EMPLOYMENT AGREEMENT

     EMPLOYMENT AGREEMENT (referred to herein as “this Agreement”) dated effective as of
July 1, 2009 (the “Effective Date”), between Virtual Radiologic Corporation, a Delaware
corporation (the “Company”), and Dr. Eduard Michel, M.D. (“Executive”).

Recitals

     WHEREAS, Executive is currently employed by the Company;

     WHEREAS, the Company desires to continue to employ Executive in the capacity of Chief Medical
Officer, and Executive desires to continue to be employed by the Company in such capacity; and

     WHEREAS, the Company and Executive desire to enter into this Agreement as to the terms of
Executive’s employment by the Company.

Agreement

     NOW THEREFORE, in consideration of the foregoing, of the mutual promises contained herein and
of other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto hereby agree as follows:

1. Position/Duties.

     (a) During the Employment Term (as defined in Section 2 below), Executive shall serve as the
Chief Medical Officer of the Company. In this capacity Executive shall have primary authority and
responsibility to assure the quality of the medical services provided by Virtual Radiologic
Professionals, LLC (“VRP”) to the Company’s clients and to other entities whose business and
affairs, other than the practice of medicine, are managed by the Company, and will have such other
duties, authorities and responsibilities commensurate with the duties, authorities and
responsibilities of persons in similar capacities in similarly sized companies and such other
duties and responsibilities as the Chief Executive Officer shall designate that are consistent with
Executive’s position as Chief Medical Officer of the Company. Executive shall report to the Chief
Executive Officer.

     (b) During the Employment Term, Executive shall devote substantially all of Executive’s
business time (excluding periods of vacation and other approved leaves of absence) to the
performance of Executive’s duties with the Company; provided the foregoing shall exclude the
Executive’s service as President of VRP and as an officer and director of other entities whose
business and affairs, other than the practice of medicine, are managed by the Company; and,
provided further, the foregoing shall not prevent Executive from (i) participating in charitable,
civic, educational, professional, community or industry affairs or, with prior written approval of
the Board of Directors of the Company (the “Board”), serving on the board of directors or
advisory boards of other companies; and (ii) managing Executive’s and Executive’s family’s personal
investments so long as such activities do not materially interfere with the performance of
Executive’s duties hereunder or create a potential business conflict or the appearance thereof. If
at any time service on any board of directors or advisory board would,

 

 

in the good faith judgment of the Board, conflict with Executive’s fiduciary duty to the
Company or create any appearance thereof, Executive shall promptly resign from such other board of
directors or advisory board after notice of the conflict is received from the Board.

     (c) Executive further agrees to serve without additional compensation as an officer and
director of any of the Company’s subsidiaries or affiliates, as the same may exist from time to
time, and agrees that any amounts received from any such subsidiary or affiliate may be offset
against the amounts due hereunder. In addition, it is agreed that the Company may assign Executive
to one of its subsidiaries or affiliates for payroll purposes providing this does not change
Executive’s role as the Chief Medical Officer of the Company.

     (d) Executive covenants and agrees, during and after the term of this Agreement, (i) to fully
and promptly comply, and (ii) to cause VRP and any other entity owned or controlled by Executive
whose business and affairs, other than the practice of medicine, are managed by the Company, to
fully and promptly comply, with all agreements between any such entity and the Company relating to
ownership succession and control, and to take all necessary or appropriate actions in connection
therewith.

2. Employment Term.

     Executive’s term of employment under this Agreement (such term of employment, as it may be
extended or terminated, is herein referred to as the “Employment Term”) shall be for a term
commencing on the Effective Date and, unless terminated earlier as provided in Section 7 hereof,
ending on the third anniversary of the Effective Date (the “Original Employment Term”);
provided that the Employment Term shall be automatically extended, subject to earlier termination
as provided in Section 7 hereof, for successive additional one (1) year periods (the
“Additional Terms”), unless, at least thirty (30) days prior to the end of the Original
Employment Term or the then current Additional Term, the Company or Executive has notified the
other in writing that the Employment Term shall terminate at the end of the then current term.

3. Base Salary.

     The Company agrees to pay Executive a base salary (the “Base Salary”) at an annual
rate of Three Hundred Fifty Thousand Dollars ($350,000), payable in accordance with the regular
payroll practices of the Company, but not less frequently than monthly. Executive’s Base Salary
shall be reviewed and may be increased, but not decreased, from time to time by the Board (or a
committee thereof). The base salary as determined herein from time to time shall constitute “Base
Salary” for purposes of this Agreement.

4. Incentive Bonus.

     During the Employment Term, Executive shall be eligible to participate in the Company’s bonus
and other incentive compensation plans and programs for the Company’s senior executives at a level
commensurate with Executive’s position. Without limiting the foregoing, Executive shall have the
opportunity to earn an annual target bonus (the “Annual Bonus”) of not less than $100,000,
or such greater amount as may be provided in an annual bonus plan approved by the Board (or a
committee thereof), contingent upon the Company’s achievement of financial and operating metrics to
be annually determined by the Board (or a

2

 

committee thereof), and upon the Executive’s achievement of individual performance goals
recommended by the Chief Executive Officer and approved by the Board (or a committee thereof).
Such annual incentive bonuses shall be paid to Executive within the sixty (60) day period following
the close of the Company’s fiscal year.

5. Equity Incentives.

     (a) Discretionary Grants. At the sole discretion of the Board or any committee of the
Board (the “Committee”) appointed to administer the Company’s Equity Incentive Plan, as may
be amended from time to time, or any successor plan (any “Stock Plan”), Executive shall be
eligible for grants of stock options and other equity awards of a level commensurate with
Executive’s position and similar to other executives of the Company.

     (b) Change of Control. Notwithstanding any other provision of this Agreement, any
Stock Plan or any equity award agreement, in the event of a Change in Control, all equity awards
(including, but not limited to, any options and restricted stock grants made prior or subsequent to
the date of this Agreement) shall fully vest and be immediately exercisable. For purposes of this
Agreement, a “Change in Control” shall mean the first of the following events to occur:

     (i) the sale, lease, exchange or other transfer, directly or indirectly, of
substantially all of the assets of the Company (in one transaction or in a series of related
transactions) to a person or entity that is not controlled by the Company;

     (ii) the approval by the shareholders of the Company of any plan or proposal for the
liquidation or dissolution of the Company;

     (iii) a merger or consolidation to which the Company is a party if the shareholders of
the Company immediately prior to effective date of such merger or consolidation have
“beneficial ownership” (as defined in Rule 13d-3 under the Exchange Act), immediately
following the effective date of such merger or consolidation, of securities of the surviving
corporation representing (A) more than 50%, but not more than 70%, of the combined voting
power of the surviving corporation’s then outstanding securities ordinarily having the right
to vote at elections of directors, unless such merger or consolidation has been approved in
advance by the Incumbent Directors (as defined below), or (B) 50% or less of the combined
voting power of the surviving corporation’s then outstanding securities ordinarily having
the right to vote at elections of directors (regardless of any approval by the Incumbent
Directors);

     (iv) any person becomes the “beneficial owner” (as defined in Rule 13d-3 under the
Exchange Act), directly or indirectly, of (A) 30% or more, but not 50% or more, of the
combined voting power of the Company’s outstanding securities ordinarily having the right to
vote at elections of directors, unless the transaction resulting in such ownership has been
approved in advance by the Incumbent Directors, or (B) 50% or more of the combined voting
power of the Company’s outstanding securities ordinarily having the right to vote at
elections of directors (regardless of any approval by the Incumbent Directors);

3

 

     (v) the Incumbent Directors cease for any reason to constitute at least a majority of
the Board; or

     (vi) any other change in control of the Company of a nature that would be required to
be reported pursuant to Section 13 or 15(d) of the Exchange Act, whether or not the Company
is then subject to such reporting requirements.

     For purposes of this definition, “Incumbent Directors” of the Company will mean any
individuals who are members of the Board on the date of this Agreement and any individual
who subsequently becomes a member of the Board whose election, or nomination for election by
the Company’s shareholders, was approved by a vote of at least a majority of the Incumbent
Directors (either by specific vote or by approval of the Company’s proxy statement in which
such individual is named as a nominee for director without objection to such nomination).

6. Employee Benefits.

     (a) Benefit Plans. Executive shall be entitled to participate in all employee benefit
plans of the Company including, but not limited to, equity, pension, thrift, profit sharing,
medical coverage, education, or other retirement or welfare benefits that the Company has adopted
or may adopt, maintain or contribute to for the benefit of its senior executives at a level
commensurate with Executive’s position, subject to satisfying any applicable eligibility
requirements.

     (b) Paid Time Off. Executive shall be entitled to paid time off in accordance with
the Company’s policies applicable to its senior executives, but in no event less than twenty (20)
days (as prorated for partial years), and additional time off for continuing medical education, all
of which may be taken at such times as Executive elects with due regard to the needs of the
Company.

     (c) Perquisites. The Company shall provide to Executive all perquisites which other
senior executives of the Company are generally entitled to receive.

     (d) Business and Entertainment Expenses. Upon presentation of appropriate
documentation, Executive shall be reimbursed in accordance with the Company’s expense reimbursement
policy for all reasonable and necessary business and entertainment expenses incurred in connection
with the performance of Executive’s duties hereunder.

7. Termination.

     Executive’s employment and the Employment Term shall terminate on the first of the following
to occur:

     (a) Disability. Upon written notice by the Company to Executive of termination due to
Disability. For purposes of this Agreement, “Disability” shall be defined as the inability
of Executive to have performed each and every material duty of Executive’s employment under this
Agreement due to a physical or mental injury, infirmity or incapacity for a period of 6 consecutive
months in any 12-month period. The existence or nonexistence of a Disability shall

4

 

be determined by the Board, acting reasonably and in good faith, taking into consideration the
opinion of an independent physician selected by the Company and reasonably acceptable to Executive.

     (b) Death. Automatically on the date of death of Executive.

     (c) Cause. Immediately upon written notice by the Company to Executive of a
termination for Cause. For purposes of this Agreement, “Cause” shall mean:

     (i) Executive shall have been indicted for a felony;

     (ii) Executive shall have been convicted of (or plead “guilty” or “nolo contendre” to
or been found guilty and not convicted of) any misdemeanor or summary offense involving
fraud, theft, misrepresentation or moral turpitude or any other misdemeanor or summary
offense that will, in the opinion of the Board, determined in good faith, adversely affect
in any material respect the Company’s prospects or reputation or Executive’s ability to
perform Executive’s obligations or duties to the Company or any of its subsidiaries; or

     (iii) The termination is evidenced by a resolution adopted in good faith by the Board
concluding that Executive:

     (A) intentionally and continually failed substantially to perform Executive’s
reasonably assigned duties with the Company (other than a failure resulting from
Executive’s incapacity due to physical or mental illness or from the assignment to
Executive of duties that would constitute Good Reason), which failure has continued
for a period of at least thirty (30) days after a written notice of demand for
substantial performance, signed by a duly authorized member of the Board, has been
delivered to Executive;

     (B) intentionally engaged in conduct which is demonstrably and materially
injurious to the Company; provided, however, that no termination of Executive’s
employment shall be for Cause as set forth in this subsection (B) until (1) there
shall have been delivered to Executive a copy of a written notice, signed by a duly
authorized member of the Board, stating that the Board has determined that Executive
has engaged in the conduct set forth in this subsection (B), and (2) Executive shall
have been provided an opportunity to be heard by the Board;

     (C) willfully or repeatedly engaged in misconduct or gross negligence in the
performance of Executive’s duties to the Company or any of its subsidiaries that has
a material detrimental effect on the Company; or

     (D) committed an act of fraud, theft or dishonesty against the Company or any
of its subsidiaries or any act or omission intended to result in the personal
enrichment of Executive or Executive’s spouse, parents, siblings, or descendants
(whether by blood or adoption and including stepchildren) or the spouses of such
individuals in violation of law or of Executive’s duty of loyalty to the Company

5

 

or its subsidiaries at the expense, directly or indirectly, of the Company or
any of its subsidiaries.

     (iv) Notwithstanding anything in the foregoing to the contrary, if Executive has been
terminated ostensibly for Cause because Executive has been indicted for a felony, and
Executive is not convicted of, or does not plead guilty or nolo contendere to, such felony
or a lesser offense (based on the same operative facts), such termination shall be deemed to
be a termination without Cause as of the date of the termination; provided, however, that,
any payments due hereunder shall be only paid after a final determination in such proceeding
is reached.

     (d) Without Cause. Upon thirty (30) days’ written notice by the Company to Executive
of an involuntary termination other than for Cause, death or Disability.

     (e) Good Reason. Upon written notice by Executive to the Company of a termination for
Good Reason, unless such the events constituting the basis for Good Reason are corrected in all
material respects by the Company within thirty (30) days following written notification by
Executive to the Company that he intends to terminate his employment hereunder for Good Reason, and
provided that any such notice is given within ninety (90) days of the occurrence of such Good
Reason and Executive actually terminates employment within twelve (12) months of the occurrence of
such Good Reason event. For purposes of this Agreement, “Good Reason” shall mean, without
the consent of Executive, the occurrence of any of the following events:

     (i) any material reduction in Executive’s status, position(s), duties or
responsibilities as an executive of the Company;

     (ii) any material reduction by the Company in Executive’s Base Salary, equity
incentives, benefits or perquisites, or a material reduction by the Company in the bonus
that Executive may earn in a given year, provided, however, that inability of the Company or
the Executive to satisfy performance objectives under any bonus plan shall not constitute
Good Reason;

     (iii) any material failure by the Company to comply with any of the material provisions
regarding Executive’s Base Salary, bonus, equity incentive, benefits and perquisites and
other benefits and amounts payable to Executive under this Agreement;

     (iv) a material change in the geographic location at which Executive must perform
Executive’s services; or

     (v) any other material breach by the Company of its obligations hereunder.

     Executive’s continued employment does not constitute consent to, or waiver of any rights
arising in connection with, any circumstances constituting Good Reason.

     (f) Without Good Reason. Upon thirty (30) days’ prior written notice by Executive to
the Company of Executive’s voluntary termination of employment without Good Reason (which the
Company may, in its sole discretion, make effective earlier than any notice date).

6

 

8. Consequences of Termination.

     Subject to Section 9, the following amounts and benefits shall be due to Executive following
Executive’s termination of employment; provided, however, that no termination payments shall be
payable hereunder if Executive has not returned to the Company all Company property used by
Executive including without limitation any automobile, computer or laptop, cell phone, Blackberry
or similar device.

     (a) Disability. Upon termination due to Disability, the Company shall pay or provide
Executive (i) any unpaid Base Salary through the date of termination; (ii) any unpaid bonus earned
with respect to any fiscal year ending on or preceding the date of termination; (iii) reimbursement
for any unreimbursed expenses incurred through the date of termination; and (iv) all other
payments, benefits or fringe benefits to which Executive may be entitled under the terms of any
applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant
or this Agreement (items (i)-(iv) being the “Accrued Amounts”). The Accrued Amounts shall
be paid to Executive within fifteen (15) days of the termination date.

     (b) Death. In the event the Employment Term ends on account of Executive’s death,
Executive’s estate shall be entitled to any Accrued Amounts. The Accrued Amounts shall be paid to
Executive within fifteen (15) days of notice of Executive’s death.

     (c) Termination for Cause or Without Good Reason. If Executive’s employment should be
terminated (i) by the Company for Cause, or (ii) by Executive without Good Reason, the Company
shall pay to Executive any Accrued Amounts. The Accrued Amounts shall be paid to Executive within
fifteen (15) days of the termination date.

     (d) Termination Without Cause or for Good Reason Other Than in Connection with a Potential
Change of Control or Actual Change of Control. If Executive’s employment by the Company is
terminated (1) by the Company other than for Cause, death or Disability, or if the Company provides
notice of its intention not to renew pursuant to Section 2, or (2) by Executive for Good Reason,
but excluding, in each case (1) and (2) any such termination in connection with a Potential Change
of Control (as defined in Section 8(e)) or an actual Change in Control, then the Company shall pay
or provide Executive with:

     (i) Accrued Amounts;

     (ii) The right to receive a pro-rata portion of Executive’s Annual Bonus for the
performance year in which Executive’s termination occurs at the time that annual bonuses are
paid to other senior executives, which pro-rata portion shall be determined by multiplying
the amount Executive would have received had employment continued through the end of the
performance year by a fraction, the numerator of which is the number of days during the
performance year of termination that Executive is employed by the Company and the
denominator of which is 365. For purposes of the foregoing, the amount the Executive would
have received shall be determined pursuant to the Company’s bonus plan with respect to
Company performance against criteria for the full fiscal year, and with respect to
individual performance based upon the Board’s

7

 

determination, in good faith, as to the extent of the Executive’s progress toward
individual performance criteria through the time of termination;

     (iii) Continuation of the Executive’s then current Base Salary as if Executive’s
employment continued for a period of twelve (12) months from the date of termination;

     (iv) A lump sum payment equal to twelve (12) times the monthly premium amount that the
Company would have been required to pay for group life insurance and group long term
disability insurance coverage if Executive had continued as an active employee of the
Company, based on the premium amounts in effect at the Executive’s date of termination
(including any known increase in such premiums); and

     (v) Subject to Executive’s timely election of any applicable continuation or conversion
coverage and continued co-payment of premiums, continued participation for twelve (12)
months in the Company’s group medical and/or dental plans which cover Executive (and
eligible dependents) upon the same terms and conditions (except for the requirements of
Executive’s continued employment) in effect on the date of termination. To the extent such
coverage cannot be provided under the Company’s group health and/or dental plans without
jeopardizing the tax status of such plans, for underwriting reasons or because of the tax
impact on Executive, the Company shall pay Executive not less frequently than monthly an
amount equal to the amount the Company would have paid for such benefits on behalf of
Executive if the benefits were provided to him as an employee. The continuation of health
benefits under this subsection shall reduce and count against Executive’s rights under the
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”).

     All benefits provided under Sections 8(d)(i) and (iv) shall be paid to Executive within
fifteen (15) days of the termination date, subject to Section 9, as applicable.

     (e) Termination Without Cause or for Good Reason in Connection with a Potential Change of
Control or Actual Change of Control. If Executive’s employment by the Company is terminated by
(1) the Company other than for Cause, death or Disability, or if the Company provides notice of its
intention not to renew pursuant to Section 2, or (2) by Executive for Good Reason, in each case (1)
and (2) in connection with a Potential Change of Control or an actual Change of Control, then the
Company shall pay or provide Executive with:

     (i) Subject to Section 9, as applicable, a lump sum payment, within fifteen (15) days
of the termination date, equal to the sum of:

     (A) all Accrued Amounts,

     (B) twelve (12) months of Base Salary,

     (C) as compensation for cancellation of Executive’s then-current Annual Bonus
opportunity, an additional 29% of annual Base Salary, and

     (D) twelve (12) times the monthly premium amount that the Company would have
been required to pay for group life insurance and group long term

8

 

disability insurance coverage if Executive had continued as an active employee
of the Company, based on the premium amounts in effect at the Executive’s date of
termination (including any known increase in such premiums); and

     (ii) Subject to Executive’s continued co-payment of premiums, continued participation
for twelve (12) months in the Company’s group medical and/or dental plans which cover
Executive (and eligible dependents) upon the same terms and conditions (except for the
requirements of Executive’s continued employment) in effect on the date of termination. To
the extent such coverage cannot be provided under the Company’s health or welfare plans
without jeopardizing the tax status of such plans, for underwriting reasons or because of
the tax impact on Executive, the Company shall pay Executive not less frequently than
monthly an amount equal to the amount the Company would have paid for such benefits on
behalf of Executive if the benefits were provided to him as an employee. The continuation
of health benefits under this subsection shall reduce and count against Executive’s rights
under COBRA.

     As used herein, a “Potential Change of Control” shall be deemed to have occurred if:
(A) the Company enters into an agreement, the consummation of which would result in the occurrence
of a Change of Control; (B) the Company or any person or entity publicly announces an intention to
take or to consider taking actions which, if consummated, would constitute a Change of Control; or
(C) the Board adopts a resolution to the effect that, for purposes of this Agreement, a Potential
Change of Control has occurred.

     (f) Code Section 409A. Payment of amounts under this Section 8 are intended to comply
with an exception to or exclusion from the requirements of Code Section 409A and this Agreement
shall in all respects be administered in accordance with such intention; provided, however, if any
payment is or becomes subject to the requirements of Code Section 409A, the Agreement as it relates
to such payment is intended to comply with the requirements of Code Section 409A. In no event may
Executive, directly or indirectly, designate the calendar year of any payment to be made under this
Agreement. The payments to be made under Section 8 are intended to be exempt from the requirements
of Code Section 409A because they are (i) non-taxable benefits, (ii) welfare benefits within the
meaning of Treas. Reg. Sec. 1.409A-1(a)(5), (iii) short-term deferrals under Treas. Reg. Sec.
1.409A-1(b)(4), or (iv) payments under a separation pay plan within the meaning of Treas. Reg. Sec.
1.409A-1(b)(9). For purposes of the limitations under Code Section 409A, each payment under this
Agreement shall be treated as a separate payment. All payments to be made upon a termination of
employment under this Agreement may only be made upon a “separation from service” as defined under
Code Section 409A. All reimbursements to be made under this Agreement that constitute deferred
compensation subject to Code Section 409A shall be made in accordance with the requirements of
Treas. Reg. Sec. 1.409A-3(i)(1)(iv). If, at the time of Executive’s termination of employment,
Executive is a “specified employee” within the meaning of Code Section 409A, then any payment of an
amount that is deferred compensation payable on account of a separation from service shall be
suspended and not made until the first day of the calendar month following the end of the six (6)
month period following Executive’s termination of employment.

     (g) Parachute Payments; Potential Reduction in Payments.

9

 

     (i) Any provision of any Stock Plan or any equity award agreement (including the
limitations of Section 10.2 of the Equity Incentive Plan) relating to “parachute payments”
under Section 280G(b)(2) of the Internal Revenue Code of 1986, as amended (the
“Code”), shall not apply to any equity award granted, at any time, to the Executive
unless the parties agree in writing to the contrary, including their express intent to
override the substance and effect of this Section 8(g)(i).

     (ii) The following terms shall have the following meanings for purposes of this Section
8(g).

     (A) “Excise Tax” shall mean the excise tax imposed by Section 4999 of
the Code, together with any interest or penalties imposed with respect to such
excise tax.

     (B) “Net After-Tax Receipt” shall mean the present value (as determined
in accordance with Sections 280G(b)(2)(A)(ii) and 280G(d)(4) of the Code) of a
Payment net of all taxes imposed on Executive with respect thereto under Sections 1
and 4999 of the Code and under applicable state and local laws, determined by
applying the highest marginal rate under Section 1 of the Code and under state and
local laws which applied to Executive’s taxable income for the immediately preceding
taxable year, or such other rate(s) as Executive certifies, in Executive’s sole
discretion, as likely to apply to him in the relevant tax year(s).

     (C) “Payment” shall mean any payment or distribution in the nature of
compensation (within the meaning of Section 280G(b)(2) of the Code) to or for the
benefit of Executive, whether paid or payable pursuant to this Agreement or
otherwise.

     (D) “Reduced Amount” shall mean the greatest amount of Agreement
Payments that can be paid that would not result in the imposition of the Excise Tax
if the Accounting Firm determines to reduce Agreement Payments pursuant to Section
8(g)(iii).

     (iii) The Company’s current independent public accounting firm, or such other
nationally recognized certified public accounting firm as may be designated by the Company
(the “Accounting Firm”), shall determine whether any Payment would subject Executive
to the Excise Tax as a result of a “change in ownership or control” of the Company (within
the meaning of Section 1.280G-1 of the Department of the Treasury Regulations). In the
event the Accounting Firm determines that any Payment would subject the Executive to the
Excise Tax, then the Payments shall be reduced to the Reduced Amount if the Accounting Firm
determines that Executive would have a greater Net After-Tax Receipt of aggregate Payments
if the Payments paid or payable under this Agreement (the “Agreement Payments”) were
reduced to the Reduced Amount. Any reduction of the Payments shall be made in the following
order: (1) options with an exercise price above the fair market value of the stock, provided
the options give rise to a Payment; (2) pro rata among amounts that constitute deferred
compensation under Code

10

 

Section 409A; and (3) reduction of any remaining payments in the manner determined by
the Accounting Firm.

     (iv) All determinations required to be made under Section 8(g)(iii) shall be made
fifteen (15) business days of the receipt of notice from the Company that there has been a
Payment, or such earlier time as is requested by the Company, and shall be accompanied by
detailed supporting calculations provided both to the Company and Executive. The notice of
Payment from the Company to the Accounting Firm shall occur no later than the date of the
Payment. In the event that the Accounting Firm is serving as accountant or auditor for the
individual, entity or group effecting the Change of Control, or in the event that the
Accounting Firm fails to make the determination required hereby for any reason (including
the Company’s failure to provide the Accounting Firm of notice of the Payment as provided
above), Executive may appoint another nationally recognized accounting firm to make the
determinations required hereunder (which accounting firm shall then be referred to as the
Accounting Firm hereunder). All fees and expenses of the Accounting Firm shall be borne
solely by the Company. Any determination by the Accounting Firm shall be binding upon the
Company and Executive.

     (v) As a result of the uncertainty in the application of Section 4999 of the Code at
the time of the initial determination by the Accounting Firm hereunder, it is possible that
amounts will have been paid or distributed by the Company to or for the benefit of Executive
pursuant to this Agreement which should not have been so paid or distributed
(“Overpayment”) or that additional amounts which will have not been paid or
distributed by the Company to or for the benefit of Executive pursuant to this Agreement
should have been so paid or distributed (“Underpayment”). In the event that the
Accounting Firm believes the Internal Revenue Service would have a 75% or greater
probability of success based upon the assertion of a deficiency by the Internal Revenue
Service against either the Company or Executive for an Overpayment, Executive shall pay any
such Overpayment to the Company together with interest at the applicable federal rate
provided for in Section 7872(f)(2) of the Code; provided, however, that no amount
shall be payable by Executive to the Company if and to the extent such payment would not
either reduce the amount on which Executive is subject to tax under Section 1 and Section
4999 of the Code or generate a refund of such taxes. In the event that the Accounting Firm,
based upon controlling precedent or substantial authority, determines that an Underpayment
has occurred, any such Underpayment shall be paid promptly (and in no event later than sixty
(60) days following the date on which the Underpayment is determined) by the Company to or
for the benefit of Executive together with interest at the applicable federal rate provided
for in Section 7872(f)(2) of the Code.

9. Release.

     Any and all amounts payable and benefits or additional rights provided pursuant to this
Agreement beyond Accrued Amounts shall only be payable if Executive delivers to the Company a
general release of all claims of Executive occurring up to the release date in the form of
Exhibit A hereto (with such insertions or changes therein as may be necessary in the
reasonable opinion of counsel for the Company to make it valid and encompassing under applicable
law). The Company shall provide such release to Executive within five (5) days of

11

 

Executive’s termination of employment and Executive must deliver such executed release to the
Company within twenty one (21) days of presentation thereof by the Company to Executive, or such
other longer or shorter period as may be required by then applicable law.

10. Restrictive Covenants.

     (a) Confidentiality. Executive shall not, directly or indirectly, use, make
available, sell, disclose or otherwise communicate to any person, other than in the course of
Executive’s assigned duties and for the benefit of the Company, either during the Employment Term
or at any time thereafter, any nonpublic proprietary or confidential information, knowledge or data
relating to the Company or any of its subsidiaries or affiliates that has been obtained by
Executive during Executive’s employment by the Company or has been obtained pursuant to any
consulting services provided by Executive to Company prior to Executive’s employment by the
Company. For purposes of this Agreement, non-public proprietary information means information
proprietary to the Company that is not generally known (including any “trade secret” within the
meaning of the Economic Espionage Act of 1996, Title 18 U.S.C. §1839) about the Company’s
customers, products, services, personnel, pricing, sales strategy, technology, methods, processes,
research, development, finances, systems, techniques, accounting, purchasing and plans. All
information disclosed to Executive or to which Executive obtains access, whether originated by him
or by others, during the period that Executive is an employee of the Company (such period being
referred to as the “Employment Period”) (whether prior to the Effective Date or
thereafter), shall be presumed to be non-public proprietary information if it is so treated by the
Company or if Executive has a reasonable basis to believe it to be such. The foregoing shall not
apply to information to the extent that it (i) was known to the public prior to its disclosure to
Executive; (ii) becomes known to the public subsequent to disclosure to Executive through no
wrongful act of Executive or any representative of Executive; or (iii) Executive is required to
disclose by applicable law, regulation or legal process (provided that Executive provides the
Company with prior notice of the contemplated disclosure and reasonably cooperates with the Company
at its expense in seeking a protective order or other appropriate protection of such information).
Notwithstanding clauses (i) and (ii) of the preceding sentence, Executive’s obligation to maintain
such disclosed information in confidence shall not terminate where only portions of the information
are in the public domain.

     (b) Non-solicitation. During the Employment Term and for the two year period
thereafter, Executive shall not, directly or indirectly, individually or on behalf of any other
person, firm, corporation or other entity, knowingly solicit, aid or induce (i) any employee of or
consultant to the Company or any of its subsidiaries or affiliates to leave such employment or
engagement in order to accept employment with or render services to or with any other person, firm,
corporation or other entity unaffiliated with the Company or knowingly take any action to
materially assist or aid any other person, firm, corporation or other entity in identifying or
hiring any such employee or (ii) any customer of the Company or any of its subsidiaries or
affiliates to purchase goods or services then sold by the Company or any of its subsidiaries or
affiliates from another person, firm, corporation or other entity or assist or aid any other
persons or entity in identifying or soliciting any such customer.

     (c) Noncompetition. Executive acknowledges that Executive performs services of a
unique nature for the Company that are irreplaceable, and that Executive’s performance of such

12

 

services to a competing business will result in irreparable harm to the Company. Accordingly,
during the Employment Term and for the two year period thereafter, Executive shall not, directly or
indirectly, own, manage, operate, control, be employed by (whether as an employee, consultant,
independent contractor or otherwise, and whether or not for compensation) or render services to any
person, firm, corporation or other entity, in whatever form, engaged in any business of the same
type as any business in which the Company or any of its subsidiaries or affiliates is engaged on
the date of termination or in which they have proposed, on or prior to such date, to be engaged in
on or after such date, in any locale of any country in which the Company or its subsidiaries
conducts business. This Section 10(c) shall not prevent Executive from owning not more than one
percent of the total shares of all classes of stock outstanding of any publicly held entity engaged
in such business, nor will it restrict Executive from rendering services to charitable
organizations, as such term is defined in Section 501(c) of the Code.

     (d) Non-disparagement. Neither Executive nor the Company (for purposes hereof, the
Company shall mean the Company together with its executive officers and directors and not any other
employees) shall make any public statements that disparage the other party, or in the case of the
Company, its respective subsidiaries, affiliates, employees, officers, directors, products or
services. Notwithstanding the foregoing, statements made in the course of sworn testimony in
administrative, judicial or arbitral proceedings (including, without limitation, depositions in
connection with such proceedings) shall not be subject to this Section 10(d).

     (e) Equitable Relief and Other Remedies. Executive acknowledges and agrees that the
Company’s remedies at law for a breach or threatened breach of any of the provisions of this
Section 10 would be inadequate and, in recognition of this fact, Executive agrees that, in the
event of such a breach or threatened breach, in addition to any remedies at law, the Company,
without posting any bond, shall be entitled to obtain equitable relief in the form of specific
performance, temporary restraining order, a temporary or permanent injunction or any other
equitable remedy which may then be available.

     (f) Reformation. If it is determined by a court of competent jurisdiction in any
state or other jurisdiction that any restriction in this Section 10 is excessive in duration or
scope or is unreasonable or unenforceable under the laws of that state or jurisdiction, it is the
intention of the parties that such restriction may be modified or amended by the court to render it
enforceable to the maximum extent permitted by the law of that state or jurisdiction.

     (g) Survival of Provisions. The obligations contained in this Section 10 shall
survive the termination or expiration of Executive’s employment with the Company and shall be fully
enforceable thereafter.

11. Inventions and Other Intellectual Property.

     (a) Assignment of Inventions and Works Limitation of Assignment in Certain Cases.
Executive acknowledges that Executive will exercise Executive’s inventive and creative abilities
for the benefit of the Company. Executive therefore assigns and transfers to the Company
Executive’s entire right, title and interest in and to all Inventions. Executive agrees that all
such Inventions are the sole property of the Company. For purposes of this Agreement,
“Inventions” shall include but not be limited to all ideas, improvements, designs and
discoveries whether or

13

 

not patentable and whether or not reduced to practice, made or conceived by Executive (whether
made solely by Executive or jointly with others) which relate in any manner to the business, work
or research and development of the Company, its subsidiaries or affiliates, or result from and are
suggested by any task assigned to Executive or any work performed by Executive for or on behalf of
the Company, its predecessors in interest or any related entity. The foregoing definition does not
however, include an Invention for which no equipment, supplies, facility, or confidential
information of the Company was used and that was developed entirely on Executive’s own time and
that (i) does not directly relate to the Company’s business, research or development, or (ii) does
not result from any work performed by Executive for the Company.

     Executive agrees that all Works are the sole property of the Company, and shall, to the extent
possible, be considered works made for hire for Company within the meaning of Title 17 of the
United States Code; provided, however, that if Executive is domiciled in California or if any of
the Work is created in California, then such Work shall not be a work made for hire. If for any
reason any Work is not deemed to be a work made for hire, then Executive assigns and transfers to
the Company Executive’s entire right, title and interest in and to such Work, and Executive further
waives all of Executive’s rights under the United States Copyright Act and under any other
country’s copyright law, including any rights provided in 17 U.S.C. §§ 106 and 106A, for any and
all purposes for which such Work and any derivative works thereof may be used, and any rights of
attribution and integrity or any other “moral rights of authors” with respect to such Work and any
derivative works thereof and any uses thereof to the full extent now or hereafter permitted by the
laws of the United States of America or the laws of any other country. For purposes of this
Agreement, “Works” shall include but not be limited to all copyrightable works created by Executive
(whether solely by Executive or jointly with others) during the Employment Period, or any time
thereafter, which relate in any manner to the business, work or research and development of the
Company, its subsidiaries or affiliates, or result from and are suggested by any task assigned to
Executive or any work performed by Executive for or on behalf of the Company, its subsidiaries or
affiliates.

     If any such assignment is invalid or ineffective for any reason, then Executive hereby grants
Company a perpetual, royalty-free, non-exclusive, worldwide license to fully exploit any
intellectual property or propriety rights in such Inventions and Works and any patents and
copyrights (or other intellectual property or propriety registrations or applications) resulting
therefrom.

     (b) Disclosure of Inventions, Works and Patents. Executive agrees that in connection
with any Invention or Work:

     (i) Executive will disclose such Invention promptly in writing to the President, Chief
Executive Officer or Board of the Company, in order to permit the Company to claim rights to
which it may be entitled under this Agreement.

     (ii) Executive will, at the Company’s request, promptly execute a written assignment of
title to the Company for any Invention required to be assigned by this Article
(“Assignable Invention”), and Executive will preserve any such Assignable Invention
as confidential information of the Company.

14

 

     (iii) Executive will give to the relevant contact person at the Company a copy of such
Work. Executive will, at the Company’s request, promptly execute a written assignment of
title to the Company for any such Work.

     (iv) Upon request, Executive agrees to assist the Company or its nominee (at its
expense) during and at any time subsequent to the Employment Period in every reasonable way
to obtain for its own benefit patents and copyrights for such Assignable Inventions and such
Works in any and all countries, which Inventions and Works shall be and remain the sole and
exclusive property of the Company or its nominee whether or not patented or copyrighted.
Executive agrees to execute such papers and perform such lawful acts as the Company deems to
be necessary to allow it to exercise all right, title and interest in such patents and
copyrights.

     (c) Execution of Documents. In connection with this Section 11, Executive further
agrees to execute, acknowledge and deliver to the Company or its nominee upon request (at its
expense) all such documents, including applications for patents and copyrights and assignments of
inventions, patents and copyrights to be issued therefore, as the Company may determine necessary
or desirable to apply for and obtain letters, patents and copyrights on such Assignable Inventions
and such Works in any and all countries and/or to protect the interest of the Company or its
nominee in such inventions, such Works, patents and copyrights, and to vest title thereto in the
Company, or its nominee.

     (d) Maintenance of Records. Executive agrees to keep and maintain adequate and
current written records of all Inventions and Works made or created by Executive (in the form of
notes, sketches, drawings and other typical forms), which records shall be available to and remain
the sole property of the Company at all times.

     (e) Prior Inventions. It is understood that all inventions, if any, patented or
unpatented, which Executive made prior to Executive’s first day as an employee of or consultant or
contractor to the Company, its predecessors in interest or any related entity (and which have not
been otherwise assigned or transferred to the Company) are excluded from the scope of this
Agreement.

     To preclude any possible uncertainty, Executive has set forth on Exhibit B attached
hereto a complete list of all Executive’s prior inventions, if any, including numbers of all
patents and patent applications, and a brief description of all unpatented inventions that are not
the property of a previous employer or other person and which have not been otherwise assigned or
transferred to the Company. Executive represents and covenants that the list is complete and that,
if no items are on the list, Executive has no such prior inventions. Executive agrees to notify
the Company in writing before Executive makes any disclosure or performs any work on behalf of the
Company which appears to threaten or conflict with proprietary rights Executive claims in any
invention or idea. In the event of Executive’s failure to give such notice, Executive agrees that
Executive will make no claim against the Company with respect to any such inventions or ideas.

     (f) Trade Secrets and Intellectual Property of Others. Executive represents that
Executive’s performance of all the terms of this Agreement does not and will not breach any

15

 

noncompetition or non-solicitation agreement, or any agreement to keep proprietary
information, knowledge or data acquired by Executive in confidence or in trust prior to the
Employment Period, and Executive will not disclose to the Company or induce the Company to use any
confidential or proprietary information or material belonging to any previous employer or other
person. Executive agrees not to enter into any agreement either written or oral in conflict
herewith.

     (g) Non Infringement. Executive represents that the work product that Executive
provides to the Company, including the Inventions and the Works, and Company’s use thereof in their
indented manner: (a) do not and will not infringe or violate the copyright or trade secret rights
of any other party; and (b) to the best of Executive’s knowledge, do not and will not infringe or
violate the actual or prospective patent or trademark rights of any other party. If at any time
during or after the Employment Period, Executive has reason to believe that the foregoing
representation is no longer true, then Executive shall promptly inform Company of such belief and
the reasons therefor.

     (h) Other Obligations. Executive acknowledges that the Company from time to time may
have agreements with other persons or with the U.S. Government or governments of other countries,
or agencies thereof, which impose obligations or restrictions on the Company regarding inventions
made during the course of work thereunder or regarding the confidential nature of such work.
Executive agrees to be bound by all such obligations and restrictions and to take all action
necessary to discharge the obligations of the Company thereunder.

12. Assignments.

     (a) This Agreement is personal to each of the parties hereto. Except as provided in Section
12(b) below, no party may assign or delegate any rights or obligations hereunder without first
obtaining the written consent of the other party hereto.

     (b) The Company will require that any successor (whether direct or indirect, by purchase,
merger, consolidation or otherwise) to all or substantially all of the assets or business of the
Company to expressly assume and agree to perform this Agreement in the same manner and to the same
extent that the Company would be required to perform it if no such succession had taken place.

13. Notice.

     For the purpose of this Agreement, notices and all other communications provided for in this
Agreement shall be in writing and shall be deemed to have been duly given (i) on the date of
delivery if delivered by hand, (ii) on the date of transmission, if delivered by confirmed
facsimile, (iii) on the first business day following the date of deposit if delivered by guaranteed
overnight delivery service, or (iv) on the fourth business day following the date delivered or
mailed by United States registered or certified mail, return receipt requested, postage prepaid,
addressed as follows:

16

 

     If to Executive:

At the address (or to the facsimile number) shown on the records of the Company.

     If to the Company:

Virtual Radiologic Corporation

11995 Singletree Lane, Suite 500

Minneapolis, MN 55344

Attention: Chief Executive Officer

Fax: (952) 942-3361

or to such other address as either party may have furnished to the other in writing in accordance
herewith, except that notices of change of address shall be effective only upon receipt.

14. Section Headings; Inconsistency.

     The section headings used in this Agreement are included solely for convenience and shall not
affect, or be used in connection with, the interpretation of this Agreement.

15. Severability.

     The provisions of this Agreement shall be deemed severable and the invalidity of
unenforceability of any provision shall not affect the validity or enforceability of the other
provisions hereof.

16. Counterparts.

     This Agreement may be executed in several counterparts, each of which shall be deemed to be an
original but all of which together will constitute one and the same instrument.

17. Indemnification.

     The Company hereby agrees to indemnify Executive and hold him harmless to the fullest extent
permitted by law and under the bylaws of the Company against and in respect to any and all actions,
suits, proceedings, claims, demands, judgments, costs, expenses (including reasonable attorney’s
fees), losses, and damages resulting from Executive’s good faith performance of Executive’s duties
and obligations with the Company. The Company shall cover Executive under directors and officers
liability insurance during the Term and thereafter in the same amount and to the same extent as the
Company covers its other officers and directors (if at all).

18. Governing Law and Venue.

     The validity, interpretation, construction and performance of this Agreement shall be governed
by the laws of the State of Minnesota without regard to its conflicts of law principles. Subject to
Section 19, each party to this Agreement consents to the jurisdiction over it of the courts of the
State of Minnesota in the City of Minneapolis, and the United States Courts in the District of
Minnesota and agrees that any personal service of process may be made by registered

17

 

or certified mail to the notice address as set forth in Section 13 hereof, and as the same may
be changed from time to time as provided therein.

19. Arbitration.

     Any dispute or controversy arising under or in connection with this Agreement shall be
submitted to arbitration in accordance with the rules of the American Arbitration Association then
in effect in Minneapolis Minnesota before a panel of three (3) arbitrators who shall be
knowledgeable in executive employment law, who shall be independent of, and have no ex parte
communications with, the parties or their representatives, and who shall render written findings of
fact, conclusions of law and order. In addition to any other inherent powers, arbitrators shall
have the express powers to order a party to comply with or desist from breaching any of the terms
of this Agreement. The determination of the arbitrators shall be final and binding upon the parties
and may be entered as a final judgment in any court of competent jurisdiction. The parties shall
equally share the costs of arbitration. Nothing herein, however, shall deprive a party of the right
to seek equitable relief from the courts to restrain or enjoin the other from a breach this
Agreement pending the empanelling of the arbitrators or their final determination.

20. Waiver and Modification.

     No provision of this Agreement may be modified, waived or discharged unless such waiver,
modification or discharge is agreed to in writing and signed by Executive and such officer or
director as may be designated by the Board. No waiver by either party hereto at any time of any
breach by the other party hereto of, or compliance with, any condition or provision of this
Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar
provisions or conditions at the same or at any prior or subsequent time.

21. Entire Agreement.

     This Agreement together with all exhibits hereto merges all prior negotiations or agreements
and sets forth the entire agreement of the parties hereto in respect of the subject of the matter
contained herein. No agreements or representations, oral or otherwise, express or implied, with
respect to the subject matter hereof have been made by either party which are not expressly set
forth in this Agreement.

22. Withholding.

     The Company may withhold from any and all amounts payable under this Agreement such foreign,
federal, state and local taxes as may be required to be withheld pursuant to any applicable law or
regulation.

23. Survival.

     The provisions of Sections 8, 9, 10, 11, 12, 13, 17, 18, 19, 22 and 23 shall survive
termination of this Agreement for whatever reason.

18

 

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
written above.

	 	 	 	 	 
	 	COMPANY

Virtual Radiologic Corporation

 	 
	 	By:  	/s/
Robert C. Kill	 
	 	 	Name:  	Robert C. Kill	 
	 	  	Its:
President and Chief Executive Officer	 
	 
	 	EXECUTIVE

 	 
	 	By:  	/s/
Eduard Michel, M.D., Ph.D.	 
	 	 	 	 
	 	 	 	 
	 

19

 

EXHIBIT A

FORM OF RELEASE

AGREEMENT AND GENERAL RELEASE

     Virtual Radiologic Corporation, its affiliates, subsidiaries, divisions, successors and
assigns and the current, future and former employees, officers, directors, trustees and agents
thereof (collectively referred to throughout this Agreement as the “Company”) and
                     Executive’s heirs, executors, administrators, successors and assigns (collectively
referred to throughout this Agreement and General Release as “Executive”) agree:

     1. Last Day of Employment. Executive’s last day of employment with the Company is
[INSERT TERMINATION DATE]. In addition, effective as of [INSERT TERMINATION DATE], Executive
resigns from Executive’s position as                      of the Company and will not be eligible for
any benefits or compensation after [INSERT TERMINATION DATE], other than as specifically provided
in the employment agreement between the Company and Executive dated effective as of
                    , 20___ (the “Employment Agreement”), subject to Executive’s executing,
delivering and not revoking Appendix 1 hereto. Executive further acknowledges and agrees that,
after [INSERT TERMINATION DATE], Executive will not represent himself as being a director,
employee, officer, trustee, agent or representative of the Company for any purpose and will not
make any public statements relating to the Company, other than general statements relating to
Executive’s position, title or experience with the Company, subject to the confidentiality
provision under Section 10(a) of the Employment Agreement and in no event will Executive make any
statements as an agent or representative of the Company. In addition, effective as of [INSERT
TERMINATION DATE], Executive resigns from all offices, directorships, trusteeships, committee
memberships and fiduciary capacities held with, or on behalf of, the Company or any benefit plans
of the Company. These resignations will become irrevocable as set forth in Section 3 below.

     2. Consideration. The parties acknowledge that this Agreement and General Release is
being executed in accordance with Section 9 of the Employment Agreement.

     3. Revocation. Executive may revoke this Agreement and General Release for a period
of calendar days following the day Executive executes this Agreement and General Release. Any
revocation within this period must be submitted, in writing, to Virtual Radiologic Corporation and
state, “I hereby revoke my acceptance of our Agreement and General Release.” The revocation must
be personally delivered or mailed to the attention of the Chief Executive Officer, Virtual
Radiologic Corporation, 11995 Singletree Lane, Suite 500, Minneapolis, MN 55344, or the Company’s
then current regular business address, and postmarked within seven (7) calendar days of execution
of this Agreement and General Release. This Agreement and General Release shall not become
effective or enforceable until the revocation period has expired. If the last day of the
revocation period is a Saturday, Sunday, or legal holiday in the State of Minnesota, then the
revocation period shall not expire until the next following day which is not a Saturday, Sunday, or
legal holiday.

 

 

     4. General Release of Claims. Executive knowingly and voluntarily releases and
forever discharges the Company from any and all claims, causes of action, demands, fees and
liabilities of any kind whatsoever, whether known and unknown, against the Company, Executive has,
has ever had or may have as of the date of execution of this Agreement and General Release,
including, but not limited to, any alleged violation of:

	 	•	 	The National Labor Relations Act, as amended;
	 
	 	•	 	Title VII of the Civil Rights Act of 1964, as amended;
	 
	 	•	 	The Civil Rights Act of 1991;
	 
	 	•	 	Sections 1981 through 1988 of Title 42 of the United States Code, as amended;
	 
	 	•	 	The Employee Retirement Income Security Act of 1974, as amended;
	 
	 	•	 	The Immigration Reform and Control Act, as amended;
	 
	 	•	 	The Americans with Disabilities Act of 1990, as amended;
	 
	 	•	 	The Age Discrimination in Employment Act of 1967, as amended;
	 
	 	•	 	The Older Workers Benefit Protection Act of 1990;
	 
	 	•	 	The Worker Adjustment and Retraining Notification Act, as amended;
	 
	 	•	 	The Occupational Safety and Health Act, as amended;
	 
	 	•	 	The Family and Medical Leave Act of 1993;
	 
	 	•	 	The Minnesota Civil Rights Act, as amended;
	 
	 	•	 	The Minnesota Minimum Wage Law, as amended;
	 
	 	•	 	Equal Pay Law for Minnesota, as amended;
	 
	 	•	 	Any other foreign, federal, state or local civil or human rights law or any other
local, state, federal or foreign law, regulation or ordinance;
	 
	 	•	 	Any public policy, contract, tort, or common law; or
	 
	 	•	 	Any allegation for costs, fees, or other expenses including attorneys’ fees incurred
in these matters.

Notwithstanding anything herein to the contrary, the sole matters to which this Agreement and
General Release do not apply are: (i) Executive’s rights of indemnification and directors and
officers liability insurance coverage, if any, to which Executive was entitled immediately prior to

2

 

[INSERT TERMINATION DATE] with regard to Executive’s service as an officer of the Company;
(ii) Executive’s rights under any tax-qualified pension or claims for accrued vested benefits under
any other employee benefit plan, policy or arrangement maintained by the Company or under COBRA;
(iii) Executive’s rights under the provisions of the Employment Agreement which are intended to
survive termination of employment; or (iv) Executive’s rights as a stockholder.

     5. No Claims Permitted. Executive waives Executive’s right to file any charge or
complaint against the Company arising out of Executive’s employment with or separation from the
Company before any foreign, federal, state or local court or any foreign, federal, state or local
administrative agency, except where such waivers are prohibited by law. This Agreement and General
Release, however, does not prevent Executive from filing a charge with the Equal Employment
Opportunity Commission, any other federal government agency, and/or any government agency
concerning claims of discrimination, although Executive waives Executive’s right to recover any
damages or other relief in any claim or suit brought by or through the Equal Employment Opportunity
Commission or any other state or local agency on behalf of Executive under the Age Discrimination
in Employment Act, Title VII of the Civil Rights Act of 1964 as amended, the Americans with
Disabilities Act, or any other federal or state discrimination law, except where such waivers are
prohibited by law.

     6. Affirmations. Executive affirms Executive has not filed, has not caused to be
filed, and is not presently a party to, any claim, complaint, or action against the Company in any
forum or form. Executive further affirms that Executive has been paid and/or has received all
compensation, wages, bonuses, commissions, and/or benefits to which Executive may be entitled and
no other compensation, wages, bonuses, commissions and/or benefits are due to him, except as
provided in the Employment Agreement. Executive also affirms Executive has no known workplace
injuries.

     7. Confidentiality; Cooperation; Return of Property. Executive agrees not to disclose
any information regarding the circumstances surrounding the cessation of Executive’s employment, or
the existence, terms, or conditions of this Agreement and General Release, to any person or entity
whatsoever, including without limitation, any members of the media (including, but not limited to,
print journalists, newspapers, radio, television, cable, satellite programs, or Internet media) or
any Internet web page or “chat room,” or any other entity or person, with the exception of
Executive’s spouse, accountant, tax advisor, and/or attorneys. Notwithstanding the aforementioned
provision, nothing herein shall preclude Executive from divulging any information to any agency of
the federal, state, or local government pursuant to an official request by such government agency
or pursuant to court order (provided that Executive provides the Company with prior notice of the
contemplated disclosure and reasonably cooperates with the Company at its expense in seeking a
protective order or other appropriate protection of such information). Executive agrees to
reasonably cooperate with the Company and its counsel in connection with any investigation,
administrative proceeding or litigation relating to any matter that occurred during Executive’s
employment in which Executive was involved or of which Executive has knowledge. The Company will
reimburse Executive for any reasonable pre-approved out-of-pocket travel, delivery or similar
expenses incurred in providing such service to the Company. Executive represents that Executive has
returned to the Company

3

 

all property belonging to the Company, including but not limited to any leased vehicle,
laptop, cell phone, keys, access cards, phone cards and credit cards.

     8. Governing Law and Interpretation. This Agreement and General Release shall be
governed and conformed in accordance with the laws of the State of Minnesota without regard to its
conflict of laws provision. In the event Executive or the Company breaches any provision of this
Agreement and General Release, Executive and the Company affirm either may institute an action to
specifically enforce any term or terms of this Agreement and General Release. Should any provision
of this Agreement and General Release be declared illegal or unenforceable by any court of
competent jurisdiction and should the provision be incapable of being modified to be enforceable,
such provision shall immediately become null and void, leaving the remainder of this Agreement and
General Release in full force and effect. Nothing herein, however, shall operate to void or
nullify any general release language contained in the Agreement and General Release.

     9. Non-admission of Wrongdoing. Executive agrees neither this Agreement and General
Release nor the furnishing of the consideration for this Release shall be deemed or construed at
any time for any purpose as an admission by the Company of any liability or unlawful conduct of any
kind.

     10. Amendment. This Agreement and General Release may not be modified, altered or
changed except upon express written consent of both parties wherein specific reference is made to
this Agreement and General Release.

     11. Entire Agreement. This Agreement and General Release sets forth the entire
agreement between the parties hereto and fully supersedes any prior agreements or understandings
between the parties; provided, however, that notwithstanding anything in this Agreement and General
Release, the provisions in the Employment Agreement which are intended to survive termination of
the Employment Agreement, including but not limited to those contained in Section 10 thereof, shall
survive and continue in full force and effect. Executive acknowledges Executive has not relied on
any representations, promises, or agreements of any kind made to him in connection with Executive’s
decision to accept this Agreement and General Release.

     EXECUTIVE HAS BEEN ADVISED THAT HE HAS UP TO TWENTY-ONE (21) CALENDAR DAYS TO REVIEW THIS
AGREEMENT AND GENERAL RELEASE AND HAS BEEN ADVISED IN WRITING TO CONSULT WITH AN ATTORNEY PRIOR TO
EXECUTION OF THIS AGREEMENT AND GENERAL RELEASE.

     EXECUTIVE AGREES ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS AGREEMENT AND GENERAL
RELEASE DO NOT RESTART OR AFFECT IN ANY MANNER THE ORIGINAL TWENTY-ONE (21) CALENDAR DAY
CONSIDERATION PERIOD.

     HAVING ELECTED TO EXECUTE THIS AGREEMENT AND GENERAL RELEASE, TO FULFILL THE PROMISES SET
FORTH HEREIN, AND TO RECEIVE THE SUMS AND BENEFITS IN SET FORTH IN THE EMPLOYMENT AGREEMENT,

4

 

EXECUTIVE FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTERS INTO THIS AGREEMENT AND
GENERAL RELEASE INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS HE HAS OR MIGHT HAVE AGAINST THE
COMPANY.

     IN WITNESS WHEREOF, the parties hereto knowingly and voluntarily executed this Agreement and
General Release as of the date set forth below:

	 	 	 	 	 
	 	Virtual Radiologic Corporation

 	 
	 	By:  	 	 
	 	 	 	 
	 	Its:  	 	 
	 
	 	 	 
	 	By:  	
 	 
	 	 	 	 
	 	 	 	 
	 

 

Re: Agreement and General Release

Dear                     :

This letter confirms that on [INSERT DATE], I personally sent to you the enclosed Agreement and
General Release. You have until [INSERT DATE] to consider this Agreement and General Release, in
which you waive important rights, including those under the Age Discrimination in Employment Act of
1967. To this end, we advise you to consult with an attorney of your choosing prior to executing
this Agreement and General Release.

	 	 	 	 	 
	 	Regards,

	 
	 	Name:	 	 
	 	 	 
	 	Title:	 	 
	 

5

 

APPENDIX 1

Chief Executive Officer

Virtual Radiologic Corporation

11995 Singletree Lane, Suite 500

Minneapolis, MN 55344

Re: Agreement and General Release

Dear Sir or Madam:

On [INSERT DATE] I executed an Agreement and General Release between Virtual Radiologic Corporation
and me. I was advised by Virtual Radiologic Corporation, in writing, to consult with an attorney
of my choosing, prior to executing this Agreement and General Release.

More than seven (7) calendar days have expired since I executed the above-mentioned Agreement and
General Release. I have at no time revoked my acceptance or execution of that Agreement and
General Release and hereby reaffirm my acceptance of it. Therefore, in accordance with the terms
of our Agreement and General Release, I request payment of the monies and benefits described in the
Employment Agreement (as defined in the Agreement and General Release).

Regards,

Signed:                                        

 

 

EXHIBIT B

TO

VIRTUAL RADIOLOGIC CORPORATION

EMPLOYMENT AGREEMENT

     Executive has indicated on this Exhibit all Inventions (as defined in the Employment Agreement) in
which Executive owned any right or interest prior to time Executive became an employee of the
Corporation. Executive agrees that any present or future Inventions not listed in this Appendix
are subject to assignment under the attached Employment Agreement.

	 	 	 	 	 
	 

	 	Brief Description of
	 	Right, Title or Interest
	 

	 	Inventions
	 	and Date Acquired

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]